We treated human TC cells (K1, MDA-T68, MDA-T32, TPC1) with (1S,3R)-RSL3 (RSL3), a small-molecule inhibitor of GPX4 and examined the effects on ferroptosis, tumor cell survival and migration, spheroid formation, oxidative stress, DNA damage repair response, and mTOR signaling pathway in vitro
Material in Section 8.4
Gastrointestinal side effects represent one of the most common challenges when starting GLP-1 receptor agonist therapy, with diarrhea occurring in approximately one-quarter of patients during initial dose escalation
When the 60 mg vial makes financial sense You are at a maintenance dose of 7.5 mg or higher (you will use the vial within the stability window) You have already titrated using smaller vials and know your target dose You are comfortable with reconstitution and precise syringe measurements You can store the vial properly for the entire duration When smaller vials make more sense You are just starting tirzepatide and do not know your dose yet You are microdosing at very low amounts (1-2.5 mg) You want to test a new vendor or batch before committing to a large purchase Your storage conditions are not ideal (unreliable refrigeration, travel) Syringe selection and measurement precision The syringe you use matters more than most people realize
Researchers can save an additional 10% when signing up for their email list
If using a particularly thin gauge needle (31G or smaller), consider using a slightly larger gauge (29G or 28G) for reconstitution, then switching to the finer needle for drawing doses
